Journal articleCancer Chemother Pharmacol2010
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
- Journal
- Cancer Chemother Pharmacol
- Published
- 24 October 2009
- Citations
- 17
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsSafety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma NCT00327327↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.